Recent News

• 09.17.2025 - Biogen Receives European Commission Approval for ZURZUVAE® (zuranolone), the First and Only Treatment Approved for Women with Postpartum Depression in Europe
• 09.04.2025 - Sangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at International Congress of Inborn Errors of Metabolism 2025
• 09.04.2025 - September 4, 2025 - September 6, 2025 : 9th International Congress on Neuropathic Pain
• 09.04.2025 - September 4, 2025 - September 6, 2025 : 9th International Congress on Neuropathic Pain
• 09.04.2025 - Wells Fargo Health Care Conference
• 09.04.2025 - Wells Fargo Health Care Conference
• 09.03.2025 - Cantor Global Healthcare Conference
• 09.03.2025 - Cantor Global Healthcare Conference
• 09.02.2025 - Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer’s Disease Under Fast Track Status
• 09.02.2025 - Biogen and Stoke Therapeutics Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome

Recent Filings

• 09.11.2025 - 8-K Current report
• 09.04.2025 - 8-K Current report
• 08.26.2025 - 4 Statement of changes in beneficial ownership of securities
• 08.26.2025 - 4 Statement of changes in beneficial ownership of securities
• 08.26.2025 - 4 Statement of changes in beneficial ownership of securities
• 08.26.2025 - 4 Statement of changes in beneficial ownership of securities
• 08.26.2025 - 4 Statement of changes in beneficial ownership of securities